Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

Stroke survivors were more likely to have little or no disability after 90 days if a clot was removed from a large brain artery followed by the injection of the clot-dissolving medication tenecteplase ...

The bolus thrombolytic agent tenecteplase narrowly failed to show noninferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients ...

Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...

The safety and efficacy of treatment with intravenous tenecteplase before endovascular thrombectomy in patients with acute ischemic stroke due to large-vessel occlusion remain uncertain. In this ...

The bolus thrombolytic, tenecteplase, was non-inferior to alteplase, which is given by a bolus followed by an infusion, for functional outcomes in acute ischemic stroke patients treated within 4½ ...

DALLAS, Feb. 1, 2024 — Compared with the standard clot-busting medication alteplase, the newer clot-buster tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) ...

Compared with the standard clot-busting medication alteplase, the newer clot-buster tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) stroke in mobile stroke ...

Two randomized trials found that intra-arterial urokinase and tenecteplase did not improve functional outcomes after mechanical thrombectomy in selected stroke patients. However, these results do not ...